The results of 3 studies have suggested that C-11 choline positron emission tomography/computerized tomography (PET/CT) scans can be used as a staging and possible therapeutic tool for patients with prostate cancer.
One study found that C-11 choline PET/CT scans, although not necessarily better, can be utilized as a staging tool instead of multiple x-rays.
Radiotherapy following surgery for breast cancer reduces the chances of cancer recurrence by 50% over the next 10 years, andit minimizes the risk of breast cancer mortality by one-sixth for the 15 years following surgery, a study led by Oxford University researchers has found.
Older women diagnosed with hormone-sensitive breast cancer are more likely to live longer and less likely to experience cancer recurrence when treated with the drug Femara (letrozole) as opposed to tamoxifen, a long-term follow-up study published online October 21 in The Lancet Oncology shows.
Although many patients with cancer have benefited from new drug discoveries over the last decade, a common side effect of these newly developed therapies may be inadvertent effects on the thyroid gland, according to a report published online in the Journal of the National Cancer Institute.
Epidemiology and Burden of Disease
ADCETRIS™ (brentuximab vedotin), a new CD30-directed antibody-drug conjugate (ADC), was approved by the U.S. Food and Drug Administration (FDA) on August 19, 2011, for the treatment of patients with relapsed or refractory Hodgkin lymphoma (HL) after failure of autologous stem cell transplant (ASCT) or after failure of at least 2 prior multiagent chemotherapy regimens. ADCETRIS is also indicated for the treatment of patients with systemic anaplastic large cell lymphoma (ALCL) after failure of at least 1 prior multiagent chemotherapy regimen.1
In the September issue, we published an editorial entitled “I Am a Nurse Practitioner, NOT a Mid-Level Provider,” in which author Alison Moriarty Daley provided an argument against this phrase. We asked our online reading community what they think about “mid-level provider.”
A recent study shows postmenopausal women with new-onset breast tenderness after beginning estrogen and progestin therapy may have an increased risk of breast cancer compared to women who don’t suffer breast tenderness. Researchers from UCLA’s Jonsson Comprehensive Cancer Center conducted the study, which appears in the early online edition of the peer-reviewed journal Breast Cancer Research and Treatment.
SAN FRANCISCO—A number of interventions can help reduce breast cancer among women at high risk, but uptake is sluggish, and there can be confusion about which agent to prescribe to a given patient. Seema Khan, MD, professor of surgery at Northwestern University Feinberg School of Medicine, Chicago, addressed the topic of pharmacologic risk reduction at the 2011 Breast Cancer Symposium.
To sign up for our newsletter or print publications, please enter your contact information below.
